Your session is about to expire
← Back to Search
Uproleselan for Acute Myeloid Leukemia
Study Summary
This trial is studying a new drug, uproleselan, to see if it can help leukemia patients.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been diagnosed with Acute Promyelocytic Leukemia.I have had a stem cell transplant before.My kidney function is reduced.My leukemia is not caused by a transplant but may be due to a genetic mutation like RUNX1.I can understand and am willing to sign the consent form, or my guardian can.I had severe brain involvement but it's better now.My lung function is significantly reduced or I need extra oxygen.I am mostly able to carry out daily activities.I weigh at least 10 kilograms.I am receiving a bone marrow or stem cell transplant from a perfectly matched donor.My white blood cell count is very low due to treatment.I have previously been treated with uproleselan.My cancer is in early remission or newly diagnosed and didn't respond well to initial treatments.I am between 1 and 39 years old.My disease has come back multiple times.I currently have an infection that is not well-controlled.
- Group 1: Uproleselan with pre-transplant conditioning
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Who meets the inclusionary criteria for this trial?
"This study is looking for 28 participants between the ages of 12 months and 30 who have leukemia, myelocytic, acute. In order to be eligible, participants must also meet the following criteria: Have newly diagnosed disease or disease in first relapse that is refractory (defined as marrow with >1% leukemic blasts by MDF or persistence of extramedullary disease) to at least 2 cycles of induction/re-induction chemotherapy., This sample will be used for eligibility as well as correlative biomarkers. Please see section 9.2 for details regarding collection, processing, and shipping of the sample"
Are subjects of this experiment restricted to those over the age of majority?
"The eligibility requirements for this study state that potential participants must fall between 12 months and 30 years old."
Are we recruiting participants for this research right now?
"If you are interested in participating in this clinical trial, you may be eligible! This study was first posted on October 6th, 2020 and has since been updated."
What are the main goals that this trial is hoping to achieve?
"The sponsor of this study, GlycoMimetics Incorporated, has reported that the primary outcome measure for this trial will be Dose Limiting Toxicity (DLT) Phase 2. This will be measured over a period of time spanning from Day -8 pre-transplant to post-transplant Day +30. In addition to the primary outcome, this study will also assess secondary outcomes including 12-month Leukemia-Free Survival (LFS), Uproleselan Pharmacokinetics, and Relapse Rate at the RP2D."
Share this study with friends
Copy Link
Messenger